Capital International Sarl Has $20.67 Million Stock Holdings in Royalty Pharma PLC $RPRX

Capital International Sarl boosted its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 45.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 534,896 shares of the biopharmaceutical company’s stock after buying an additional 166,334 shares during the period. Capital International Sarl’s holdings in Royalty Pharma were worth $20,668,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of RPRX. Lloyd Advisory Services LLC. acquired a new position in Royalty Pharma in the 4th quarter valued at about $30,000. Smartleaf Asset Management LLC grew its stake in Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 790 shares during the last quarter. Private Trust Co. NA grew its stake in Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 288 shares during the last quarter. Larson Financial Group LLC grew its stake in Royalty Pharma by 31.9% in the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 306 shares during the last quarter. Finally, Fifth Third Bancorp grew its stake in Royalty Pharma by 16.9% in the 3rd quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 362 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Insider Buying and Selling at Royalty Pharma

In other Royalty Pharma news, EVP Marshall Urist sold 13,684 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $52.75, for a total value of $721,831.00. Following the completion of the sale, the executive vice president owned 18,197 shares of the company’s stock, valued at $959,891.75. The trade was a 42.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 64,399 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $53.98, for a total transaction of $3,476,258.02. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 199,185 shares of company stock valued at $10,082,926 in the last quarter. Company insiders own 18.84% of the company’s stock.

Royalty Pharma Stock Performance

NASDAQ RPRX opened at $55.87 on Friday. The company has a quick ratio of 2.66, a current ratio of 2.66 and a debt-to-equity ratio of 0.86. The company has a market capitalization of $32.17 billion, a P/E ratio of 38.01, a P/E/G ratio of 1.54 and a beta of 0.43. Royalty Pharma PLC has a 12-month low of $33.37 and a 12-month high of $56.07. The firm has a 50-day moving average price of $50.81 and a two-hundred day moving average price of $45.01.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. The firm had revenue of $630.58 million during the quarter, compared to the consensus estimate of $881.69 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. Analysts anticipate that Royalty Pharma PLC will post 5.05 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a $0.235 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a yield of 1.7%. Royalty Pharma’s payout ratio is currently 63.95%.

Analyst Ratings Changes

RPRX has been the topic of a number of research reports. Citigroup upped their price target on shares of Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. The Goldman Sachs Group reiterated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, February 12th. UBS Group upped their price target on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. JPMorgan Chase & Co. upped their price target on shares of Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Finally, TD Cowen reiterated a “buy” rating on shares of Royalty Pharma in a research note on Friday, February 27th. Seven analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $53.71.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.